COPD_A_329454 2869..2881

Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, 220, Taiwan; Department of Chemical Engineering and Materials Science, Yuan Ze University, Zhongli, Taoyuan, 320, Taiwan; Changhua Christian Hospital, Thoracic Medicine Research Center, Changhua, 500, Taiwan; Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan; Division of Chest, Department of Internal Medicine, Poh-Ai Hospital, Luodong, 265, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, National Cheng Kung University, College of Medicine and Hospital, Tainan, 701, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan; Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan; Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, 613, Taiwan; Department of Internal Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, 970, Taiwan; Big Data Center, Changhua Christian Hospital, Changhua, Changhua Christian Hospital, Changhua, 500, Taiwan; Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, 402, Taiwan; Department of Recreation and Holistic Wellness, MingDao University, Changhua, 523, Taiwan

[1]  B. Oldenburg,et al.  Chronic care model in the diabetes pay-for-performance program in Taiwan: Benefits, challenges and future directions , 2021, World journal of diabetes.

[2]  Chien-Te Lee,et al.  Effect of a Pay-for-Performance Program on Renal Outcomes Among Patients With Early-Stage Chronic Kidney Disease in Taiwan , 2021, International journal of health policy and management.

[3]  V. Willey,et al.  Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy , 2021, Journal of managed care & specialty pharmacy.

[4]  Te-Wei Ho,et al.  Impact of tobacco-related chronic obstructive pulmonary disease on developmental trajectories of comorbidities in the Taiwan population , 2020, Scientific Reports.

[5]  N. Chavannes,et al.  Gaps in COPD Guidelines of Low- and Middle-Income Countries , 2020, Chest.

[6]  Theo Vos.  GBD: The Basics , 2020 .

[7]  V. Iyer,et al.  Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the real world: current understanding, barriers, and solutions. , 2019, Current opinion in pulmonary medicine.

[8]  Emanuela Tudorache,et al.  Risk factors of chronic obstructive pulmonary disease exacerbations , 2019, The clinical respiratory journal.

[9]  P. Meredith,et al.  Modern Innovative Solutions in Improving Outcomes in Chronic Obstructive Pulmonary Disease (MISSION COPD): Mixed Methods Evaluation of a Novel Integrated Care Clinic , 2019, Interactive journal of medical research.

[10]  Shih-Yi Lin,et al.  Pay-for-performance for shared care of diabetes in Taiwan. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[11]  A. Darzi,et al.  Changing health behaviors using financial incentives: a review from behavioral economics , 2019, BMC Public Health.

[12]  S. Fernando,et al.  An Analysis of Pay-for-Performance Schemes and Their Potential Impacts on Health Systems and Outcomes for Patients , 2019, Critical care research and practice.

[13]  Y. Hsueh,et al.  The effects of a schizophrenia pay-for-performance program on patient outcomes in Taiwan. , 2019, Health services research.

[14]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[15]  C. Rhee,et al.  Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives , 2019, Advances in Therapy.

[16]  Chin-Chou Wang,et al.  The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study , 2018, International journal of chronic obstructive pulmonary disease.

[17]  A. O’Regan,et al.  Adherence to COPD management guidelines in general practice? A review of the literature , 2018, Irish Journal of Medical Science (1971 -).

[18]  Y. Wen,et al.  Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010 , 2017, International journal of chronic obstructive pulmonary disease.

[19]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[20]  Chin-Chou Wang,et al.  Impact of overweight and obesity on acute exacerbations of COPD – subgroup analysis of the Taiwan Obstructive Lung Disease cohort , 2017, International journal of chronic obstructive pulmonary disease.

[21]  S. Lee,et al.  Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims , 2017, Tuberculosis and respiratory diseases.

[22]  S. Annavarapu,et al.  Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population , 2017, International journal of chronic obstructive pulmonary disease.

[23]  T. Schermer,et al.  Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD , 2017, Respiratory Research.

[24]  Chih-Cheng Hsu,et al.  Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  K. Hsu,et al.  The effectiveness of a pay for performance program on diabetes care in Taiwan: A nationwide population-based longitudinal study. , 2016, Health policy.

[26]  N. Huang,et al.  Disease-specific Pay-for-Performance Programs: Do the P4P Effects Differ Between Diabetic Patients With and Without Multiple Chronic Conditions? , 2016, Medical care.

[27]  S. H. Cheng,et al.  Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care , 2016, JAMA oncology.

[28]  T. Welte,et al.  Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)-A large population-based cohort study. , 2016, Health policy.

[29]  Chung-Pin Li,et al.  Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan? , 2016, PloS one.

[30]  J. Goddard,et al.  Acute exacerbation of COPD , 2016, Respirology.

[31]  L. Hang,et al.  COPD in Taiwan: a National Epidemiology Survey , 2015, International journal of chronic obstructive pulmonary disease.

[32]  T. Lu,et al.  Ten leading causes of death in Taiwan: A comparison of two grouping lists. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[33]  H. Chiu,et al.  Cost-Effectiveness of a Diabetes Pay-For-Performance Program in Diabetes Patients with Multiple Chronic Conditions , 2015, PloS one.

[34]  D. Mannino,et al.  Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting. , 2015, Chronic obstructive pulmonary diseases.

[35]  S. Straus,et al.  Guideline uptake is influenced by six implementability domains for creating and communicating guidelines: a realist review. , 2015, Journal of clinical epidemiology.

[36]  Jinping Zheng,et al.  Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey , 2015, Asia Pacific family medicine.

[37]  C. Roberts,et al.  Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit , 2015, PloS one.

[38]  Te-Wei Ho,et al.  In-Hospital and One-Year Mortality and Their Predictors in Patients Hospitalized for First-Ever Chronic Obstructive Pulmonary Disease Exacerbations: A Nationwide Population-Based Study , 2014, PloS one.

[39]  C. McDonald,et al.  Level of adherence to the GOLD strategy document for management of patients admitted to hospital with an acute exacerbation of COPD , 2014, Respirology.

[40]  A. Joshi,et al.  An Overview of Chronic Disease Models: A Systematic Literature Review , 2014, Global journal of health science.

[41]  G. Cesana,et al.  The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients , 2014, PloS one.

[42]  J. Goddard,et al.  Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. , 2014, Journal of thoracic disease.

[43]  L. Petersen.  Pay for performance: what we measure matters. , 2013, The virtual mentor : VM.

[44]  David M Cutler,et al.  The potential for cost savings through bundled episode payments. , 2012, The New England journal of medicine.

[45]  Shou-Hsia Cheng,et al.  A Longitudinal Examination of a Pay-for-Performance Program for Diabetes Care: Evidence From a Natural Experiment , 2012, Medical care.

[46]  J. Struijs,et al.  Pay-for-performance in disease management: a systematic review of the literature , 2011, BMC health services research.

[47]  Louise Lemieux-Charles,et al.  How can we improve guideline use? A conceptual framework of implementability , 2011, Implementation science : IS.

[48]  Mei-Shu Lai,et al.  The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program? , 2011, Health services research.

[49]  K. Khunti,et al.  Has pay for performance improved the management of diabetes in the United Kingdom? , 2010, Primary care diabetes.

[50]  M. Lai,et al.  A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. , 2010, The American journal of managed care.

[51]  C. Chiang.  Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan , 2008, Respirology.

[52]  Jacqueline A Pugh,et al.  Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. , 2007, Archives of internal medicine.

[53]  Hoangmai H Pham,et al.  Care patterns in Medicare and their implications for pay for performance. , 2007, The New England journal of medicine.

[54]  G. Molenberghs.  Applied Longitudinal Analysis , 2005 .

[55]  D. King,et al.  Improving Chronic Obstructive Pulmonary Disease (COPD) Symptoms Using a Team-Based Approach , 2020 .

[56]  S. P. Akpabio.  World Health Organisation , 1983, British Dental Journal.